Jennifer Dorantes, MD
Internal Medicine · Carmel, INNPI 1508870221
Payments from drug & device makers
Across 165 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$573
- Novo Nordisk$473
- Amgen$264
- Lilly USA, LLC$263
- AstraZeneca$227
- GSK$138
- plus $915 from 21 others
What the payments were for
- Food & beverage$2,852100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $573 |
| Novo Nordisk | 28 | $473 |
| Amgen | 14 | $264 |
| Lilly USA, LLC | 16 | $263 |
| AstraZeneca | 14 | $227 |
| GSK | 9 | $138 |
| Pfizer | 8 | $134 |
| Bayer | 5 | $121 |
| Astellas Pharma US Inc | 5 | $93 |
| Boehringer Ingelheim | 5 | $82 |
| Merck | 5 | $69 |
| Exact Sciences | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$2,852 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $95,060 |
| MounjaroTirzepatide | 65 | $69,899 |
| JardianceEmpagliflozin | 45 | $47,392 |
| EliquisApixaban | 43 | $34,708 |
| RybelsusSemaglutide | 18 | $26,357 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 25 | $22,300 |
| MyrbetriqMirabegron | 13 | $13,819 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $13,601 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 24 | $5,310 |
| PremarinEstrogens, Conjugated | 13 | $4,735 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $4,631 |
| DuleraMometasone/Formoterol | 12 | $4,036 |
| Atorvastatin Calcium | 402 | $2,742 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,613 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $2,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $473 | $121,416109 claims |
| Lilly USA, LLCMounjaro | $263 | $69,89965 claims |
| Boehringer IngelheimJardiance | $82 | $47,39245 claims |
| PfizerEliquis, Premarin | $134 | $39,44356 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $50 | $22,30025 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $13,81913 claims |
| GSKShingrix | $138 | $5,31024 claims |
| MerckDulera | $69 | $4,03612 claims |
| AbbVieSynthroid | $573 | $1,72028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Carmel
- Brian UlmerCarmel$29K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.